相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The Promise of Combining Radiation Therapy With Immunotherapy
Justin C. Jagodinsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy
Takahiro Yamazaki et al.
NATURE IMMUNOLOGY (2020)
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy
Stanley I. Gutiontov et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng et al.
NATURE COMMUNICATIONS (2020)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Tumor-reprogrammed resident T cells resist radiation to control tumors
Ainhoa Arina et al.
NATURE COMMUNICATIONS (2019)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression (vol 128, pg 805, 2018)
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors
Jason J. Luke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial
Harvey C. Quon et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
Marka R. Crittenden et al.
SCIENTIFIC REPORTS (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
Abul Azad et al.
EMBO MOLECULAR MEDICINE (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (vol 29, pg 285, 2016)
Haidong Tang et al.
CANCER CELL (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
Alexander Filatenkov et al.
CLINICAL CANCER RESEARCH (2015)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell-Mediated Killing
Hua Liang et al.
JOURNAL OF IMMUNOLOGY (2013)
Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: A comparison of acute toxicity and quality of life
Suneil Jain et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy
Clint Park et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Stereotactic body radiation therapy in multiple organ sites
Robert D. Timmerman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)